AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33489806 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox-proportional hazards models
Number of subjects: 8800
Study 33489806 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression
Number of subjects: 8800
Study 33490196 — intervention group
Group type: COMPARATOR
Intervention: SOX (S-1 plus oxaliplatin)
Number of subjects: 0
Study 33490196 — intervention group
Group type: EXPERIMENTAL
Intervention: SOXA (S-1 plus oxaliplatin combined with apatinib)
Number of subjects: 0
Study 33490196 — intervention group
Group type: EXPERIMENTAL
Intervention: SOXAP (S-1 plus oxaliplatin combined with apatinib and camrelizumab)
Number of subjects: 0
Study 33490296 — intervention group
Group type: EXPERIMENTAL
Intervention: UCB-MSC-HA implantation
Number of subjects: 114
Study 33490296 — intervention group
Group type: COMPARATOR
Intervention: Microfracture
Number of subjects: 114
Study 33490640 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile outreach team approach with oral anti-TB treatment under DOTS
Number of subjects: 200
Study 33490640 — intervention group
Group type: COMPARATOR
Intervention: Facility-based DOTS treatment according to WHO recommendations
Number of subjects: 200
Study 33490640 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile outreach team approach
Number of subjects: 200
Study 33490707 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy (SABR) - 20Gy single fraction followed by pembrolizumab - 200 mg every 3 weeks for 8 cycles
Number of subjects: 30
Study 33490863 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical variables and genome-wide variants
Number of subjects: 2799
Study 33490863 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic analyses
Number of subjects: 2799
Study 33491053 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary resection
Number of subjects: 44
Study 33491277 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg) intravenously every 21 days
Number of subjects: 12
Study 33491317 — intervention group
Group type: EXPERIMENTAL
Intervention: PwO perceptions
Number of subjects: 2000
Study 33491317 — intervention group
Group type: EXPERIMENTAL
Intervention: HCP perceptions
Number of subjects: 2000
Study 33491317 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation to lose weight
Number of subjects: 2000
Study 33491317 — intervention group
Group type: EXPERIMENTAL
Intervention: HCP perceptions of PwO motivation
Number of subjects: 2000
Study 33491317 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to discussing weight
Number of subjects: 2000
Study 33491317 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of weight with HCPs
Number of subjects: 2000
Study 33491317 — intervention group
Group type: EXPERIMENTAL
Intervention: Main barrier to weight loss
Number of subjects: 2000
Study 33491317 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful weight loss
Number of subjects: 2000
Study 33491668 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of allogeneic human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) at a dosage of 1 × 10^6 to 3 × 10^6 cells/kg, administered as 3 injections every 2 weeks for 8-24 months.
Number of subjects: 6
Study 33492231 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention (6-month duration)
Number of subjects: 450
Study 33492231 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 450
Study 33492231 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 450
Study 33492239 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly subcutaneously administered methotrexate
Number of subjects: 12
Study 33492239 — intervention group
Group type: COMPARATOR
Intervention: Daily oral azathioprine or 6-mercaptopurine
Number of subjects: 12
Study 33492239 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneously administered adalimumab (ADA)
Number of subjects: 12
Study 33492239 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 12
Study 33492239 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's school attendance
Number of subjects: 12
Study 33492239 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' productivity (WPAI-CD-CG questionnaire)
Number of subjects: 12
Study 33492239 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (QoL) measurements using EuroQol 5-Dimension questionnaires
Number of subjects: 12
Study 33492438 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-42, 60 mg three times weekly for 3 weeks of a 28-day cycle
Number of subjects: 17
Study 33492438 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-42
Number of subjects: 17
Study 33492438 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-42 in patients with NF2 or meningioma
Number of subjects: 17
Study 33492554 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetic long-term absorbable mesh (Phasix®)
Number of subjects: 215
Study 33492745 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade placement of fistula needle
Number of subjects: 164
Study 33492893 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ocular assessment consisting of visual acuity, intraocular pressure, visual field testing, and imaging of the retina and optic nerve with spectral-domain optical coherence tomography.
Number of subjects: 0
Study 33492893 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives along with a validated patient education program.
Number of subjects: 0
Study 33492893 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine program.
Number of subjects: 0
Study 33492893 — intervention group
Group type: COMPARATOR
Intervention: Standard in-person care.
Number of subjects: 0
Study 33492986 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab 3 mg/kg every 2 weeks via intravenous infusion until disease progression or unacceptable toxicity
Number of subjects: 190
Study 33492986 — intervention group
Group type: EXPERIMENTAL
Intervention: Toripalimab 3 mg/kg every 2 weeks via intravenous infusion
Number of subjects: 190
Study 33493046 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 4654
Study 33493046 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 4654
Study 33493046 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment effect (CAS-to-CEA)
Number of subjects: 4654
Study 33493297 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative exposure to elvitegravir
Number of subjects: 0
Study 33493297 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative exposure to raltegravir
Number of subjects: 0
Study 33493297 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative exposure to stavudine
Number of subjects: 0
Study 33493312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous golimumab (80 mg/m2 at weeks 0, 4, then every 8 weeks through week 52 plus MTX weekly through week 28)
Number of subjects: 127
Study 33493312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous golimumab
Number of subjects: 127
Study 33493377 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroparesis patients
Number of subjects: 715
Study 33493392 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosidenib (100 mg twice daily and 300-1200 mg once daily)
Number of subjects: 253
Study 33493392 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Number of subjects: 253
Study 33493590 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular surgery procedures in patients with COVID-19 infection
Number of subjects: 75
Study 33493590 — intervention group
Group type: EXPERIMENTAL
Intervention: Age >65 years
Number of subjects: 75
Study 33493590 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA classification IV
Number of subjects: 75
Study 33493590 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative lymphocyte count <0.6 (×10^9/L)
Number of subjects: 75
Study 33493688 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-procedure tramadol
Number of subjects: 1335
Study 33493688 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-procedure epidural opioids
Number of subjects: 1335
Study 33493688 — intervention group
Group type: COMPARATOR
Intervention: Short-acting opioids
Number of subjects: 1335
Study 33493688 — intervention group
Group type: COMPARATOR
Intervention: Long-acting opioids
Number of subjects: 1335
Study 33493697 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct acting antiviral agents (DAAs) leading to sustained virologic response (SVR)
Number of subjects: 854
Study 33493778 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater positive symptoms
Number of subjects: 404
Study 33493778 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 404
Study 33493778 — intervention group
Group type: EXPERIMENTAL
Intervention: Stronger working memory
Number of subjects: 404
Study 33493778 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired clinical insight
Number of subjects: 404
Study 33493822 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraxia of Speech Rating Scale (ASRS) administered by five speech-language pathologists (SLPs)
Number of subjects: 36
Study 33494702 — intervention group
Group type: EXPERIMENTAL
Intervention: Early upper limb passive ergometry for 30 minutes
Number of subjects: 12
Study 33494702 — intervention group
Group type: COMPARATOR
Intervention: Reverse Fick method
Number of subjects: 12
Study 33494702 — intervention group
Group type: COMPARATOR
Intervention: Indirect calorimetry
Number of subjects: 12
Study 33494707 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with cardiovascular events during hospitalization for CAP
Number of subjects: 1266
Study 33494707 — intervention group
Group type: COMPARATOR
Intervention: Patients without cardiovascular events during hospitalization for CAP
Number of subjects: 1266
Study 33494793 — intervention group
Group type: EXPERIMENTAL
Intervention: ramucirumab plus paclitaxel
Number of subjects: 62
Study 33494821 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad-Shoulder intervention consisting of 1-5 individual sessions over 3 months based on 5 self-management skills.
Number of subjects: 11
Study 33494961 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified HEART score
Number of subjects: 0
Study 33494961 — intervention group
Group type: COMPARATOR
Intervention: Standard risk stratification methods
Number of subjects: 0
Study 33494963 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose recombinant full-length circumsporozoite protein-based vaccine with GLA-LSQ adjuvant
Number of subjects: 0
Study 33494963 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33495083 — intervention group
Group type: EXPERIMENTAL
Intervention: Recording an obesity diagnosis in medical notes
Number of subjects: 2331
Study 33495083 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort discussing weight with patients
Number of subjects: 2331
Study 33495083 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling motivated to help patients lose weight
Number of subjects: 2331
Study 33495083 — intervention group
Group type: COMPARATOR
Intervention: Lack of advanced formal training in obesity management
Number of subjects: 2331
Study 33495144 — intervention group
Group type: EXPERIMENTAL
Intervention: Major bleeding (MB) following LAAO
Number of subjects: 0
Study 33495264 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic clinical prediction model combining simple clinical features and measurements of host biomarkers
Number of subjects: 4900
Study 33495264 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical outcome ascertained on day 2 and day 28
Number of subjects: 4900
Study 33495293 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention for maternal GDM
Number of subjects: 0
Study 33495293 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lifestyle intervention)
Number of subjects: 0
Study 33495292 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 157
Study 33495292 — intervention group
Group type: COMPARATOR
Intervention: HbA1c monitoring
Number of subjects: 157
Study 33495309 — intervention group
Group type: EXPERIMENTAL
Intervention: Prexasertib + samotolisib
Number of subjects: 0
Study 33495312 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) plus tranylcypromine (TCP) at three dose levels: 10 mg twice daily, 20 mg twice daily, and 30 mg twice daily.
Number of subjects: 17
Study 33495385 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote-only follow-up with Remote View service
Number of subjects: 176
Study 33495476 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior treatments
Number of subjects: 429
Study 33495476 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsatellite instability
Number of subjects: 429
Study 33495476 — intervention group
Group type: EXPERIMENTAL
Intervention: CRC-specific 1kb-10Mb deletions and LINC00672 mutations
Number of subjects: 429
Study 33495476 — intervention group
Group type: EXPERIMENTAL
Intervention: FBXW7 mutations
Number of subjects: 429
Study 33495497 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplant (HCT)
Number of subjects: 133
Study 33495497 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy (CT)
Number of subjects: 133
Study 33495497 — intervention group
Group type: COMPARATOR
Intervention: Community controls
Number of subjects: 133
Study 33495742 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone pulses and tacrolimus plus standard of care (SoC)
Number of subjects: 84
Study 33495742 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC) alone
Number of subjects: 84
Study 33495752 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin 400 mcg/kg, single dose
Number of subjects: 24
Study 33495752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 33496186 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular Thrombectomy (ET)
Number of subjects: 7674
Study 33496186 — intervention group
Group type: COMPARATOR
Intervention: Bridging Thrombolysis (BT)
Number of subjects: 7674
Study 33496191 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography imaging at baseline and at 6 months
Number of subjects: 187
Study 33496357 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg every 2 weeks for up to 2 years
Number of subjects: 26
Study 33496357 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 26
Study 33496659 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaphylaxis management guidelines
Number of subjects: 0
Study 33496677 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit Zip activity tracker worn daily for 8 weeks (2 weeks prior to surgery and 6 weeks post-surgery)
Number of subjects: 62
Study 33496677 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitbit Zip worn as a clip-on device
Number of subjects: 62
Study 33496677 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of patients
Number of subjects: 62
Study 33496677 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 62
Study 33496745 — intervention group
Group type: EXPERIMENTAL
Intervention: CALGB 10403
Number of subjects: 39
Study 33496745 — intervention group
Group type: COMPARATOR
Intervention: COG AALL0232
Number of subjects: 39
Study 33496747 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg daily for 14 days per cycle combined with 8 cycles of CHOP21
Number of subjects: 78
Study 33496747 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide and CHOP
Number of subjects: 78
Study 33496754 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate or cryoprecipitate replacement for hypofibrinogenemia
Number of subjects: 137
Study 33496754 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 137
Study 33496877 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine-sparing strategy
Number of subjects: 160
Study 33496877 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine-to-all strategy
Number of subjects: 160
Study 33496877 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study 33496906 — intervention group
Group type: EXPERIMENTAL
Intervention: Trendelenburg maneuver (15° downward bed angulation)
Number of subjects: 22
Study 33496906 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid challenge (500 mL gelatin over 15 min)
Number of subjects: 22
Study 33496906 — intervention group
Group type: COMPARATOR
Intervention: Baseline-1 (supine position with 15° upward bed angulation)
Number of subjects: 22
Study 33496906 — intervention group
Group type: COMPARATOR
Intervention: Baseline-2 (same position as baseline-1)
Number of subjects: 22
Study 33497021 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-dialysis recovery time for male patients
Number of subjects: 86
Study 33497021 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-dialysis recovery time for patients with intradialytic hypotension (IDH)
Number of subjects: 86
Study 33497021 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-dialysis recovery time
Number of subjects: 86
Study 33497021 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-dialysis recovery time by gender
Number of subjects: 86
Study 33497021 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI in relation to post-dialysis recovery time
Number of subjects: 86
Study 33497061 — intervention group
Group type: EXPERIMENTAL
Intervention: REPS (Residual Neuromuscular Block Prediction Score) high (≥4)
Number of subjects: 101510
Study 33497061 — intervention group
Group type: COMPARATOR
Intervention: TOF ratio <0.90
Number of subjects: 101510
Study 33497061 — intervention group
Group type: EXPERIMENTAL
Intervention: REPS high (≥4)
Number of subjects: 101510
Study 33497524 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene correction of the c.175G>A variant in patient-derived iPSCs
Number of subjects: 0
Study 33497524 — intervention group
Group type: COMPARATOR
Intervention: Control iPSCs (coisogenic, corrected variant)
Number of subjects: 0
Study 33497776 — intervention group
Group type: EXPERIMENTAL
Intervention: Theta-burst TMS to OPA
Number of subjects: 0
Study 33497776 — intervention group
Group type: COMPARATOR
Intervention: Theta-burst TMS to OFA (active control)
Number of subjects: 0
Study 33497776 — intervention group
Group type: COMPARATOR
Intervention: Sham (no TBS stimulation)
Number of subjects: 0
Study 33498192 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery calcification (CAC) determined by Agatston and volume score
Number of subjects: 184
Study 33498192 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal aorta calcification (KS) determined by plain X-ray of the lumbar spine
Number of subjects: 184
Study 33498192 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence and extension of vascular calcification (VC)
Number of subjects: 184
Study 33498192 — intervention group
Group type: EXPERIMENTAL
Intervention: CAC and KS
Number of subjects: 184
Study 33498797 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib + Letrozole (P+L)
Number of subjects: 247
Study 33498797 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib + Fulvestrant (P+F)
Number of subjects: 247
Study 33499647 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-based cardiac rehabilitation program (12 weeks, 3 sessions per week)
Number of subjects: 29
Study 33500704 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) with or without adefovir (ADV) for 104 weeks
Number of subjects: 24
Study 33500784 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline objective clinical scoring (SCAT5)
Number of subjects: 0
Study 33500784 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive data (ImPACT)
Number of subjects: 0
Study 33500784 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes to SCAT5 and ocular, vestibular, and reaction time function (Dx 100)
Number of subjects: 0
Study 33500784 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessments (CANTAB)
Number of subjects: 0
Study 33500784 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain MRI (7 Tesla)
Number of subjects: 0
Study 33500784 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary biomarkers
Number of subjects: 0
Study 33501400 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 weekly doses of lyophilized fecal microbiota product from healthy donors
Number of subjects: 6
Study 33501650 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent-start peritoneal dialysis (PD)
Number of subjects: 991
Study 33501650 — intervention group
Group type: COMPARATOR
Intervention: Haemodialysis (HD) initiated using a CVC
Number of subjects: 991
Study 33501995 — intervention group
Group type: EXPERIMENTAL
Intervention: darunavir/cobicistat with rilpivirine and/or dolutegravir
Number of subjects: 725
Study 33501995 — intervention group
Group type: COMPARATOR
Intervention: darunavir/cobicistat alone
Number of subjects: 725
Study 33501999 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy in women with LGMDR9
Number of subjects: 22
Study 33502092 — intervention group
Group type: EXPERIMENTAL
Intervention: Heartech® left ventricular partitioning device (LVPD)
Number of subjects: 15
Study 33502111 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tacrolimus (0.03 mg/kg) administered twice daily starting 3 days prior to transplant
Number of subjects: 252
Study 33502111 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosing simulation strategy based on observed tacrolimus concentration
Number of subjects: 252
Study 33502111 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariate analysis
Number of subjects: 252
Study 33502330 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile sensing features (call logs, battery charging, screen checking)
Number of subjects: 26
Study 33502567 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-Low Doses of Therapy with Radiation (ULTRA-COVID)
Number of subjects: 2
Study 33502675 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported overall sitting time
Number of subjects: 2524
Study 33502675 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported sum of different types of sedentary behavior
Number of subjects: 2524
Study 33502675 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-based sedentary time (Actigraph GT3X accelerometers)
Number of subjects: 2524